{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T10:40:19Z","timestamp":1774867219473,"version":"3.50.1"},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,12,27]],"date-time":"2013-12-27T00:00:00Z","timestamp":1388102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bipolar Disorders"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Motivated by genetic association data implicating L\u2010type calcium channels in bipolar disorder liability, we sought to estimate the tolerability, safety, and efficacy of isradipine in the adjunctive treatment of bipolar depression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 12 patients with bipolar I or <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> depression entered this pilot, proof\u2010of\u2010concept eight\u2010week investigation and 10 returned for at least one post\u2010baseline visit. They were initiated on isradipine at 2.5\u00a0mg and titrated up to 10\u00a0mg daily, with blinded assessments of depression using the Montgomery\u2013\u00c5sberg Depression Rating Scale (<jats:styled-content style=\"fixed-case\">MADRS<\/jats:styled-content>) as well as adverse effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 10 patients, three had bipolar <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> disorder; all but two reported current episode duration longer than six months. In all, four of 10 completed the study; no significant adverse events were observed, although one subject discontinued treatment per protocol because of possible hypomanic symptoms which had resolved prior to study visit. In a mixed\u2010effects model, mean improvement in depression severity, assessed by <jats:styled-content style=\"fixed-case\">MADRS<\/jats:styled-content>, was 2.1 (standard error\u00a0=\u00a00.36) points\/week (p\u00a0&lt;\u00a00.001). Two of the 10 subjects remitted and four of the 10 subjects experienced 50% or greater symptomatic improvement with treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Isradipine merits further investigation for the treatment of bipolar depression. This preliminary trial illustrates the potential utility of genetic investigation in identifying psychiatric treatment targets.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bdi.12143","type":"journal-article","created":{"date-parts":[[2013,12,27]],"date-time":"2013-12-27T12:00:42Z","timestamp":1388145642000},"page":"199-203","source":"Crossref","is-referenced-by-count":48,"title":["Pilot investigation of isradipine in the treatment of bipolar depression motivated by genome\u2010wide association"],"prefix":"10.1111","volume":"16","author":[{"given":"Michael J","family":"Ostacher","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences Stanford University School of Medicine Palo Alto CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan V","family":"Iosifescu","sequence":"additional","affiliation":[{"name":"Mood and Anxiety Disorders Program Department of Psychiatry Icahn School of Medicine at Mount Sinai New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleena","family":"Hay","sequence":"additional","affiliation":[{"name":"Department of Psychology Yale University New Haven CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah R","family":"Blumenthal","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Center for Experimental Drugs and Diagnostics Massachusetts General Hospital Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Sklar","sequence":"additional","affiliation":[{"name":"Mood and Anxiety Disorders Program Department of Psychiatry Icahn School of Medicine at Mount Sinai New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy H","family":"Perlis","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Center for Experimental Drugs and Diagnostics Massachusetts General Hospital Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,12,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0806284"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002747"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.209"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.943"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62129-1"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.b.31122"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199810000-00009"},{"key":"e_1_2_7_9_1","volume-title":"Structured Clinical Interview for DSM\u2010IV Axis I Disorders","author":"First MB","year":"1996"},{"key":"e_1_2_7_10_1","first-page":"72","article-title":"Concordance with treatment guidelines for bipolar disorder: data from the systematic treatment enhancement program for bipolar disorder","volume":"40","author":"Dennehy EB","year":"2007","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01866-8"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"e_1_2_7_14_1","first-page":"218","volume-title":"ECDEU Assessment Manual for Psychopharmacology: US Dept Health Education and Welfare publication (ADM) 76\u2013338","author":"Guy W","year":"1976"},{"key":"e_1_2_7_15_1","first-page":"343","article-title":"SAFTEE: a technique for the systematic assessment of side effects in clinical trials","volume":"22","author":"Levine J","year":"1986","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000201934"},{"key":"e_1_2_7_17_1","unstructured":"Anonymous.Isradipine (Dynacirc) Package Insert. Available from:http:\/\/www.drugs.com\/monograph\/isradipine.html[accessed January 2013]."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.293"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008877-199711000-00019"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2010.06.019"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1000402"}],"container-title":["Bipolar Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbdi.12143","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bdi.12143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T13:26:16Z","timestamp":1696339576000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bdi.12143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,27]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1111\/bdi.12143"],"URL":"https:\/\/doi.org\/10.1111\/bdi.12143","archive":["Portico"],"relation":{},"ISSN":["1398-5647","1399-5618"],"issn-type":[{"value":"1398-5647","type":"print"},{"value":"1399-5618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,27]]}}}